119 related articles for article (PubMed ID: 7586948)
1. S-mephenytoin hydroxylation phenotypes in a Jordanian population.
Hadidi HF; Irshaid YM; Woosley RL; Idle JR; Flockhart DA
Clin Pharmacol Ther; 1995 Nov; 58(5):542-7. PubMed ID: 7586948
[TBL] [Abstract][Full Text] [Related]
2. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
[TBL] [Abstract][Full Text] [Related]
3. Analysis of mephenytoin, 4-hydroxymephenytoin and 4-hydroxyphenytoin enantiomers in human urine by cyclodextrin micellar electrokinetic capillary chromatography: simple determination of a hydroxylation polymorphism in man.
Desiderio C; Fanali S; Küpfer A; Thormann W
Electrophoresis; 1994 Jan; 15(1):87-93. PubMed ID: 8143685
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphism of S-mephenytoin 4'-hydroxylation.
Daniel HI; Edeki TI
Psychopharmacol Bull; 1996; 32(2):219-30. PubMed ID: 8783891
[TBL] [Abstract][Full Text] [Related]
5. [Determination of mephenytoin and 4'-hydroxymephenytoin in urine by high performance liquid chromatography].
Ruan ZR; Cheng YS; Ding DY
Yao Xue Xue Bao; 1994; 29(8):624-8. PubMed ID: 7985520
[TBL] [Abstract][Full Text] [Related]
6. Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans.
Partovian C; Jacqz-Aigrain E; Keundjian A; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1995 Sep; 58(3):257-63. PubMed ID: 7554698
[TBL] [Abstract][Full Text] [Related]
7. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
Wedlund PJ; Aslanian WS; McAllister CB; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1984 Dec; 36(6):773-80. PubMed ID: 6499356
[TBL] [Abstract][Full Text] [Related]
8. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
Sanz EJ; Villén T; Alm C; Bertilsson L
Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.
Wedlund PJ; Aslanian WS; Jacqz E; McAllister CB; Branch RA; Wilkinson GR
J Pharmacol Exp Ther; 1985 Sep; 234(3):662-9. PubMed ID: 4032286
[TBL] [Abstract][Full Text] [Related]
10. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.
Sohn DR; Kusaka M; Ishizaki T; Shin SG; Jang IJ; Shin JG; Chiba K
Clin Pharmacol Ther; 1992 Aug; 52(2):160-9. PubMed ID: 1505151
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans.
Küpfer A; Patwardhan R; Ward S; Schenker S; Preisig R; Branch RA
J Pharmacol Exp Ther; 1984 Jul; 230(1):28-33. PubMed ID: 6747829
[TBL] [Abstract][Full Text] [Related]
12. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans.
Fritz S; Lindner W; Roots I; Frey BM; Küpfer A
J Pharmacol Exp Ther; 1987 May; 241(2):615-22. PubMed ID: 3572817
[TBL] [Abstract][Full Text] [Related]
13. Family studies of mephenytoin hydroxylation deficiency.
Inaba T; Jurima M; Kalow W
Am J Hum Genet; 1986 May; 38(5):768-72. PubMed ID: 3717162
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.
Küpfer A; Preisig R
Eur J Clin Pharmacol; 1984; 26(6):753-9. PubMed ID: 6489416
[TBL] [Abstract][Full Text] [Related]
15. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
[TBL] [Abstract][Full Text] [Related]
16. A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin.
Küpfer A; Brilis GM; Watson JT; Harris TM
Drug Metab Dispos; 1980; 8(1):1-4. PubMed ID: 6102023
[TBL] [Abstract][Full Text] [Related]
17. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
Adedoyin A; Arns PA; Richards WO; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1998 Jul; 64(1):8-17. PubMed ID: 9695714
[TBL] [Abstract][Full Text] [Related]
18. Effects of genetically determined S-mephenytoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam.
Otani K; Yasui N; Kaneko S; Ohkubo T; Osanai T; Sugawara K; Hayashi K; Chiba K; Ishizaki T
Neuropsychopharmacology; 1997 Jan; 16(1):8-14. PubMed ID: 8981384
[TBL] [Abstract][Full Text] [Related]
19. Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin.
Zhou HH; Anthony LB; Wood AJ; Wilkinson GR
Br J Clin Pharmacol; 1990 Sep; 30(3):471-5. PubMed ID: 2223426
[TBL] [Abstract][Full Text] [Related]
20. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
Skjelbo E; Gram LF; Brøsen K
Br J Clin Pharmacol; 1993 Mar; 35(3):331-4. PubMed ID: 8471415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]